Nanotoxicology and challenges of translation

Nanomedicine

Volumn 10, Issue 20, 2015, Pages 3121-3129

  Pourgashtasbi, Ghazal ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

nanomaterials; nanotoxicology; object and knowledge formation; transformation of practices and self understanding; translation; uncertainty

Indexed keywords

NANOCARRIER; NANOMATERIAL;

ARTICLE; DRUG DELIVERY SYSTEM; EXPECTATION; KNOWLEDGE; LABORATORY; NANOMEDICINE; NANOTOXICOLOGY; NONHUMAN; PRIORITY JOURNAL; SCIENTIST; SELF CONCEPT; HUMAN; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

HUMANS; NANOMEDICINE; NANOSTRUCTURES; RISK ASSESSMENT; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84944323547     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.131     Document Type: Article

References (62)

1. Schillmeier M. Caring for complexity in nanomedicine. Nanomedicine 10(20), 3181-3193 (2015).
2. Bamrungsap S, Zhao Z, Chen T. Nanotechnology in therapeutics. A focus on nanoparticles as drug delivery system. Nanomedicine 7(8), 1253-1271 (2012).
3. Riehemann K, Schneider SW, Luger TA et al. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 48(5), 872-897 (2009).
4. Andersen TL, Berg RH. Current challenges and future directions in nanomedicine. JSM Nanotechnol. Nanomed. 1(2), 1013 (2013).
5. Schillmeier M. What ELSA/I makes big and small in Nanotechnology Research. In: Absence in Science, Security and Policy. From Research Agendas to Global Strategy, Palgrave Macmillan, Rappert B, Balmer B (Eds). Houndmills, Basingstoke, UK, 55-77 (2015).
6. Edwards SA. The Nanotech Pioneers. Where Are They Taking Us? Wiley-VCH Verlag, Weinheim, 105 (2006).
7. ISO. ISO/TS 80004-7:2011-nanotechnologies-vocabulary-part 7: diagnostics and therapeutics for healthcare (2011). www.iso.org/iso/isocatalogue/catalogue
8. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8, 2101-2141 (2011).
9. Gendelman HE, Mosley RL, Boska MD, McMillan J. The promise of nanoneuromedicine. Nanomedicine 9(2), 171-176 (2014).
10. EuroNanoMed II. Joint transnational call for proposals. European innovative research & technological development projects in nanomedicine (2014). www.euronanomed.net
11. ETP Nanomedicine. Nanomedicine 2020-contribution of nanomedicine to horizon 2020. White paper to the horizon 2020 framework programme for research and innovation-recommentations from the nanomedicine commmuity, (2013). www.etp-nanomedicine.eu/public/press-documents.
12. Institut für Technikfolgenabschätzung und Systemananlyse (ITAS). Nano safety-risk governance of manufactured nanoparticles. Final report of the project for the Science and Technology Options Assessment (STOA) Panel of the European Parliament (2012). www.itas.kit.edu/english/2012-023.php.
13. ISO. ISO/TR 13014:2012-nanotechnologies-guidance on physico-chemical characterization of engineered nanoscale materials for toxicological assessment (2012). www.iso.org/iso/catalogue-detail?csnumber=52334.
14. Duran N, Guterres SS, Alves OL. Nanotoxicology, Materials, Methods and Assessments. Springer, Heidelberg, Germany (2014).
15. Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1(1), 2-25 (2007).
16. Krug HF, Wick P. Nanotoxicology: an interdisciplinary challenge. Angew. Chem. Int. Ed. Engl. 50(6), 1260-1278 (2011).
17. Ratner M, Ratner D. Nanotechnology: A General Introduction To The Next Big Idea. Prentice Hall, NJ, USA, 7 (2003).
18. Luxenhofer R. Polymers and nanomedicine: considerations on variability and reproducibility when combining complex systems. Nanomedicine 10(20), 3109-3119 (2015).
19. ISO. ISO/TS 80004-5:2011-nanotechnologies-vocabulary-part 5: nano/bio interface (2011). www.iso.org/iso/isocatalogue/cataloguetc/catalogue
20. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PLA. Nanotoxicology Occup. Environ. 61, 727-728 (2004).
21. Monteiro-Riviere NA, Lang Tran C (Ed.). Nanotoxicology: Progress toward Nanomedicine (2nd Edition). CRC Press, FL, USA (2014).
22. Fonseca de Faria A, Mazarin de Moraes A C, Alves O. Toxicity of nanomaterials to microorganisms: mechanisms, methods, and new perspectives. In: Nanotoxicology, Materials, Methods and Assessments. Duran N, Guterres SS, Alves OL (Eds). Springer, Heidelberg, Germany, 363-405 (2014).
23. Monopoli MP, Bombelli FB, Dawson KA. Nanobiotechnology: nanoparticle coronas take shape. Nat. Nanotechnol. 6, 11-12 (2011).
24. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol. Sci. 120(1), 109-129 (2011).
25. Villaverde A (Ed.). Nanoparticles in translational science and medicine. In : Progress In Molecular Biology And Translational Science (Vol. 104). Academic Press, London, Waltham, San Diego (2011).
26. Costigliola V. From less effective to personalised medicine. Presented at: 4th European Conference for Clinical Nanomedicine (Clinam). Basel, Switzerland, 22-25 May 2011.
27. Sagnella SM, McCarroll AJ, Kavallaris M. Drug delivery: beyond active tumor targeting. Nanomedicine 10(6), 1131-37 (2014).
28. Eaton MAW, Levy L, Fontaine OMA. Delivering nanomedicines to patients: a practical guide. Nanomedicine 11(4), 983-992 (2015).
29. Hunziker P. With nanomedicine towards personalised medicine-now and future. Presented at: 4th European Conference for Clinical Nanomedicine (Clinam). Basel, Switzerland, 22-25 May 2011.
30. Sutariya VB, Pathak Y. Biointeractions of Nanomaterials. CRC Press, FL, USA (2015).
31. Hunziker P. Knowledge-based (personalized) medicine instead of "evidence-based (cohort) medicine". Eur. J. Nanomed. 4(1), 5-6 (2012).
32. Eaton MAW. How do we develop nanopharmaceuticals under open innovation? Nanomedicine 7(4), 371-75 (2011).
33. Janrao KK, Gadhave MV, Banerjee SK, Gaikwad DD. Nanoparticle induced nanotoxicity: an overview. Toxicol. Mech. Methods 23(3), 151-152 (2013).
34. Moghimi S, Farhangrazi ZS. Just so stories: the random acts of anti-cancer nanomedicine performance. Nanomed. Biol. Med. 10(8), 1661-1666 (2014).
35. Riviere JR. Of mice, men and nanoparticle biocoronas: are in vitro to in vivo correlations and interspecies extrapolations realistic? Nanomedicine 8(9), 1357-1359 (2013).
36. Shankarappa SA, Koyakutty M, Nair SV. Efficacy versus toxicity-the ying and yang in translating nanomedicines. Nanomater. Nanotechnol. 4(23), doi:10.5772/59127 (2014).
37. Bölükbas DA, Meiners S. Lung cancer nanomedicine: potentials and pitfalls. Nanomedine 10(21), doi:10.2217/NNM.15.155 (2015) (In press).
38. Doak SH, Griffiths SM, Manshian B et al. Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24(4), 285-293 (2009).
39. Van der Worp HB, Howells DW, Sena ES et al. Can animal models of disease reliably inform human studies? PLoS Med. 7(3), e1000245 (2010).
40. Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano 7(4), 2878-2882 (2013).
41. Penco S, Venco E, Lio A. Lost in translation: the need for better tools. Atla 42, 41-45 (2014).
42. Henry CJ. Unleashing the power of comparative oncology models in nanomedicine research. Eur. J. Nanomed. 7(2), 129-33 (2015).
43. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 267(1), 89-105 (2010).
44. Kurath M, Kaiser M. Fragile disziplinen: transformationsprozesse. In: Technologisierung gesellschaftlicher Zukünfte. Nanotechnologie in wissenschaftlicher, politischer und öffentlicher Praxis. Lucht P, Erlemann M, Ruiz Ben E. (Eds). Centaurius, Freiburg, 93-108 (2010).
45. Merz M. Reinventing a laboratory: nanotechnology as a resource for organizatioal change. In: Governing Future Technologies. Nanotechnology And The Rise Of An Assessment Regime. Kaiser M, Kurath M, Maasen S, Rehmann-Sutter C (Eds). Springer, Dordecht, The Netherlands, 7 (2010).
46. Günday N, Schneider M. Conference Scene: nanomedicine and nanotoxicology: future prospects and the need for translational factors for the combination of both. Nanomedicine 7(6), 811-814 (2012).
47. Latour B. Reassembling The Social. An Introduction to Actor-Network-Theory. Oxford University Press, Oxford, UK, 39 (2005).
48. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol. Sci. 120(1), 109-129 (2011).
49. Latour B. Why has critique run out of steam? From matters of fact to matters of concern. Critical Inquiry 30, 225-248 (2004).
50. Stengers I. Including nonhumans in political theory: opening Pandora's box?' In: Political Matter: Technoscience, Democracy and Public Life. Braun B, Whatmore S (Eds). University of Minnesota Press, MN, USA, 3-34 (2010).
51. Rheinberger H-J. Experimentalsysteme und epistemische Dinge. Eine Geschichte der Proteinsynthese im Reagenzglas. Suhrkamp, Frankfurt/Mainz, Germany (2006).
52. Rheinberger H-J. Experiment. Differenz. Schrift. Zur Geschichte epistemischer Dinge. Basiliken-Presse, Marburg/Lahn, Germany, 13 (1992).
53. Wickson F, Gillund F, Myhr I. Treating nanoparticles with precaution: recognising qualitative uncertainty in scientific risk assessment. In: Nano meets Macro-Social Perspectives on Nanoscale Sciences and Technologies. Kjolberg KL, Wickson F (Eds). Pan Stanford Publishing, Singapore, 445-468 (2010).
54. Hagner M, Rheinberger H-J, Wahrig-Schmidt B (Ed.). Objekte-Differenzen-Konjunkturen, Experimentalsysteme im historischen Kontext. Akademie Verlag (1994).
55. Schillmeier M. Eventful Bodies-The Cosmopolitcs Of Illness. Ashgate, Farnham, 169 (2014).
56. Latour B. Science in action. How To Follow Scientists And Engineers Through Society. Harvard University Press, MA, USA (1987).
57. Monteiro-Riviere NA, Lang Tran C. Nanotoxicology. Progress Toward Nanomedicine (2nd Edition). CRC Press, FL, USA (2014).
58. Kurath M. Negotiating nano: from assessing risks to disciplinary transformations. In: Governing Future Technologies. Nanotechnology and the Rise of an Assessment Regime. Kaiser M, Kurath M, Maasen S, Rehmann-Sutter C (Eds). Springer, Heidelberg, Germany 29 (2010).
59. Andon FT, Fadeel B. Nanotoxicology: towards safety by design. In: Nano-Oncologicals. New Targeting and Delivery Approaches. Alonso MJ, Garcia-Fuentes M (Eds). Springer, Heidelberg, Germany, 291-424 (2014).
60. Nel A, Xia T, Meng H, Xiang W et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high troughput screening. Acc. Chem. Res. 46(3), 607-621 (2013).
61. Krug HF. Nanosafety research: are we on the right track? Angew. Chem. Int. Ed. Engl. 53, 12304-12319 (2014).
62. Hartung T. A Toxicology for the 21st century-mapping the road ahead. Toxicol. Sci. 109(1), 18 (2009).